Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, orally active, and highly selective inhibitor of gastric H/K-ATPase, capable of controlling gastric acid secretion and motility, with in vitro assayed values of 0.29-0.52 μM against H/K-ATPase in swine, dogs, and humans.